Live Breaking News & Updates on Adrienneg waks

Stay updated with breaking news from Adrienneg waks. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Dr Waks on Later-Line Treatment Options in HER2+ Breast Cancer

Adrienne G. Waks, MD, discusses treatment alternatives in the third line and beyond for patients with metastatic HER2-positive breast cancer. ....

Adrienneg-waks , Dana-farber-cancer-institute , Harvard-medical-school , Clinical-research , Onclive-tv , Dana-farber-cancer-center , Her2-positive-breast-cancer , Breast-cancer ,

Combination Approaches Are on the Horizon in Later-Line HER2+ Breast Cancer Management

Adrienne G. Waks, MD, spotlights the need to understand mechanisms of resistance to second-line HER2-positive breast cancer therapies, chemotherapy-free regimens with later-line treatment potential, and the future of HER2-positive disease management. ....

Boston , Massachusetts , United-states , Dana-farber-cancer-institute , Adrienneg-waks , Harvard-medical-school , Clinical-research-at-dana-farber-cancer-institute , Clinical-research , Trastuzumab-emtansine-plus-tucatinib , Monarcher-trial , Nct02675231

HER2+ Breast Cancer Treatment Arena May Redefine the Roles of ADCs and Targeted Agents

Adrienne G. Waks, MD, spotlights the role of the HER2CLIMB regimen in patients with HER2-positive breast cancer with brain metastases, discusses unmet needs in the fourth- and later-line settings in HER2-positive disease, and explains the basis for the ongoing HER2CLIMB-02 and HER2CLIMB-04 trials within the broader ADC landscape. ....

Boston , Massachusetts , United-states , Dana-farber-cancer-institute , Adrienneg-waks , Clinical-research-at-dana-farber-cancer-institute , Harvard-medical-school , Clinical-research , Patients-with-her2-positive-breast-cancer , D , Adjuvant-trastuzumab-emtansine

Systemic Therapy Shows Increasing Promise for CNS Metastases in Breast Cancer

Nancy U. Lin, MD, provides clinical insights on the treatment of patients with breast cancer brain metastases and discusses the advantages and disadvantages of systemic therapy vs radiation therapy for this population. ....

Dana-farber-cancer-institute , Massachusetts , United-states , Boston , Adrienneg-waks , Paolo-tarantino , Erical-mayer , Sarah-sammons , Nancyu-lin , Program-for-patients , Metastatic-breast-cancer-program , Harvard-medical-school

CDK4/6 Inhibitor Selection and Sequencing Continue to Evolve in HR+ Breast Cancer

Sarah Sammons, MD, discusses the evolving role of CDK4/6 inhibitors in hormone receptor–positive breast cancer, the future of antibody-drug conjugates in triple-negative breast cancer, and the importance of educating patients about their available treatment options so they can share in the decision-making process. ....

Dana-farber-cancer-institute , Massachusetts , United-states , Boston , Chestnut-hill , Paolo-tarantino , Adrienneg-waks , Sarah-sammons , Nancyu-lin , Erical-mayer , Eli-lilly , Daiichi-sankyo